Package Leaflet: Information for the User
Ibufen400 mg Oral Powder
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Follow the administration instructions for the medication contained in this package leaflet or as indicated by your doctor or pharmacist exactly.
Package Leaflet Contents
Ibuprofen belongs to the group of medications called non-steroidal anti-inflammatory drugs (NSAIDs).
This medication is indicated in adolescents and adults:
You should consult a doctor if it worsens or does not improve after 3 days.
It is important that you use the smallest dose that relieves/controls the pain and do not take this medication for longer than necessary to control your symptoms.
Do not takeIbufen
Warnings and Precautions
Consult your doctor or pharmacist before starting to take this medication.
Cardiovascular precautions
Anti-inflammatory/analgesic medications like ibuprofen can be associated with a small increase in the risk of suffering a heart attack or stroke, especially when used in high doses. Do not exceed the recommended dose or treatment duration.
You should discuss your treatment with your doctor or pharmacist before taking Ibufen if:
Special caution is recommended with Ibufen
Skin reactions
Severe skin reactions, such as exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP), have been reported in association with Ibufen treatment. Discontinue Ibufen treatment and seek medical attention immediately if you notice any symptoms related to these severe skin reactions described in section 4.
Stop taking Ibufen and consult your doctor immediately if you experience any skin rash, mucous membrane lesions, blisters, or other signs of allergy, as these can be the first signs of a severe skin reaction. See section 4.
Ibufen can mask the signs of an infection, such as fever and pain. Consequently, Ibufen may delay the appropriate treatment of the infection, which can increase the risk of complications. This has been observed in bacterial pneumonia and bacterial skin infections related to chickenpox. If you take this medication while having an infection and the symptoms of the infection persist or worsen, consult a doctor without delay.
Similarly, this type of medication can cause fluid retention, especially in patients with heart failure and/or high blood pressure (hypertension).
Children and Adolescents
There is a risk of kidney damage in dehydrated children and adolescents.
Interference with Laboratory Tests:
Taking ibuprofen can alter the following laboratory tests:
With liver function tests: increased transaminase values.
Inform your doctor if you are going to undergo a clinical analysis and are taking or have recently taken ibuprofen.
Consult your doctor or pharmacist before starting to take Ibufen.
Use of Ibufen with Other Medications
Inform your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication.
Ibufen can affect or be affected by other medications. For example:
Other medications can also affect or be affected by Ibufen treatment. Therefore, you should always consult your doctor or pharmacist before using Ibufen with other medications.
Taking Ibufen with Food, Beverages, and Alcohol
For patients with stomach upset, it is recommended to take the medication during meals.
Consuming alcohol can increase the risk of adverse reactions.
Pregnancy, Breastfeeding, and Fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Precautions during pregnancy and in women of childbearing age
Do not take Ibufen if you are in the last 3 months of pregnancy, as it may harm the fetus or cause problems during delivery. It can cause kidney and heart problems in your fetus. It can affect your tendency and that of your baby to bleed and delay or prolong delivery more than expected. You should not take ibuprofen during the first 6 months of pregnancy unless it is strictly necessary and as indicated by your doctor. If you need treatment during this period or while trying to become pregnant, you should take the minimum dose for the shortest possible time. From the 20th week of pregnancy, ibuprofen can cause kidney problems in your fetus if taken for more than a few days, which can lead to low levels of amniotic fluid surrounding the baby (oligohydramnios) or narrowing of a blood vessel (ductus arteriosus) in the baby's heart. If you need treatment for more than a few days, your doctor may recommend additional checks.
For women of childbearing age, it should be noted that medications of this type have been associated with a decrease in fertility.
Breastfeeding
Although the medication levels in breast milk are negligible, it is recommended to consult your doctor in cases of long-term treatment or high doses during breastfeeding.
Driving and Using Machines
If you experience dizziness, vertigo, vision changes, or other symptoms while taking this medication, you should not drive or operate machinery. If you only take one dose of ibuprofen or for a short period, it is not necessary to take special precautions.
Ibuprofen can delay your reaction time, which should be taken into account before performing activities that require greater vigilance, such as driving and using machinery.
Ibufen Contains Isomalt (E-953)
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Follow the administration instructions of the medication contained in this prospectus or as indicated by your doctor or pharmacist. In case of doubt, ask your doctor or pharmacist.
Dosage
Adults andadolescents (over 12 years and >40 kg)
The recommended dose is 1 sachet (400 mg of ibuprofen) 3 times a day every 6-8 hours.
The dosage interval should be chosen according to the symptoms. Do not exceed 1,200 mg of ibuprofen (3 sachets) within 24 hours.
The lowest effective dose should be used for the shortest time necessary to relieve symptoms. If you have an infection, consult your doctor without delay if symptoms (such as fever and pain) persist or worsen (see section 2).
This medication is used for short-term treatments.
If symptoms worsen, if the fever persists for more than 3 days or the pain for more than 5 days (3 days in adolescents), you should consult a doctor.
The administration of this medication is subject to the appearance of pain or fever. As these symptoms disappear, the medication should be suspended.
Pediatric population
Do not administer to children or adolescents with a weight of less than 40 kg, as the dose does not adjust to their posology.
Elderly population (over 65 years)
The dosage should be established by the doctor, as it may be necessary to reduce the usual dose.
Patientswithkidney,liverorheartdiseases
Reduce the dose and consult your doctor. Ibuprofen should not be used in patients with severe renal or hepatic insufficiency.
Method of administration
For oral use.
Empty the contents of the sachet directly into the mouth. In patients with gastric discomfort, it is recommended to take the medication during meals.
If you take moreIbufénthan you should
If you have taken more Ibufén than you should, or have accidentally ingested the contents of the package, consult your doctor or pharmacist immediately, or the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested. It is recommended to take the package and the prospectus of the medication to the healthcare professional.
If you have taken more Ibufén than you should, or if a child has accidentally ingested the medication, consult a doctor or go to the nearest hospital to find out about the risk and ask for advice on the measures to be taken.
The symptoms of overdose may include nausea, stomach pain, vomiting (which may contain bloody sputum), gastrointestinal bleeding (see section 4), diarrhea, headache, ringing in the ears, confusion, and involuntary eye movement. Agitation, disorientation, or coma may also occur. At high doses, symptoms of drowsiness, chest pain, palpitations, loss of consciousness, convulsions (mainly in children), weakness, and dizziness, blood in the urine, low potassium levels in the blood, chills, and breathing difficulties have been reported.
Acute kidney failure and liver damage may also occur.
Asthma exacerbation is possible in asthmatics. Additionally, there may be low blood pressure and reduced breathing.
If you forget to takeIbufén
Do not take a double dose to make up for forgotten doses.
If you forget to take your corresponding dose, take it as soon as you remember. However, if the time of the next dose is very close, skip the forgotten dose and take the next dose at the usual time.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause adverse effects, although not all people suffer from them.
The frequencies have been defined as follows:
Very common:may affect more than 1 in 10 patients.
Common:may affect up to 1 in 10 patients.
Uncommon:may affect up to 1 in 100 patients.
Rare:may affect up to 1 in 1,000 patients.
Very rare:may affect up to 1 in 10,000 patients.
Frequency not known:cannot be estimated from the available data.
The following adverse effects have been observed:
Gastrointestinal disorders
The most frequent adverse effects that occur with medications containing this active ingredient are gastrointestinal: peptic ulcers, gastrointestinal bleeding, perforations (in some cases fatal), especially in elderly patients. Nausea, vomiting, diarrhea, flatulence, constipation, heartburn, abdominal pain, blood in stools, oral ulcers, worsening of ulcerative colitis, and Crohn's disease have also been observed. Gastritis has been observed less frequently.
Common:nausea, vomiting, abdominal pain, heartburn, flatulence, and constipation.
Uncommon:bleeding, stomach or duodenal ulcers.
Rare:gastric or intestinal perforation, esophageal inflammation, and ulcers or inflammation of the intestine.
Skin and subcutaneous tissue disorders
Common:skin rash.
Uncommon:skin redness, itching or skin swelling, lip swelling, facial or tongue swelling, increased nasal secretion, and breathing difficulties.
Rare:severe allergic reactions (anaphylactic shock).
Very rare:intense itching of the skin with sudden onset or blisters on the skin, joint pain, and fever (systemic lupus erythematosus), hair loss, skin reactions due to light influence. Medications containing this active ingredient may be associated, in very rare cases, with severe blistering reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, and allergic vasculitis.
Severe allergic reaction that can manifest with nausea, vomiting, facial, tongue, and throat swelling, breathing difficulties, asthma, palpitations, hypotension, or shock.
Frequency not known:generalized red scaly rash, with bumps under the skin and blisters, mainly located in skin folds, trunk, and upper limbs, accompanied by fever at the start of treatment (acute generalized exanthematous pustulosis). The skin becomes sensitive to light. Stop taking Ibufén if you experience these symptoms and seek medical attention immediately. See also section 2.
A severe skin reaction known as DRESS syndrome may occur. The symptoms of DRESS syndrome include: skin rash, lymph node inflammation, and elevated eosinophils (a type of white blood cell).
Nervous system disorders
Common:headache.
Uncommon:fatigue or drowsiness.
Very rare:aseptic meningitis (inflammation of the membranes covering the brain and spinal cord), in most cases in patients with some autoimmune disease such as systemic lupus erythematosus.
Psychiatric disorders
Common:feeling of instability and nervousness.
Uncommon:anxiety.
Rare:disorientation or confusion, depression.
Ear and labyrinth disorders
Uncommon:ringing or buzzing in the ears.
Rare:hearing difficulty.
Eye disorders
Uncommon:vision alteration.
Rare:abnormal or blurred vision.
Blood and lymphatic system disorders
Very rare:prolonged bleeding time, alterations in blood cells (the first symptoms may be: fever, sore throat, mouth ulcers, flu-like symptoms, excessive fatigue, nasal and skin bleeding).
Cardiovascular disorders
These medications may be associated with a moderate increase in the risk of suffering a heart attack ("myocardial infarction") or stroke. Edema (fluid retention), arterial hypertension, and heart failure have also been observed in association with treatments with medications of this type.
Frequency not known:chest pain, which may be a sign of a potentially severe allergic reaction called Kounis syndrome.
Renal and urinary disorders
Kidney disease.
Hepatobiliary disorders
Rare:hepatitis (liver inflammation) and jaundice (yellowing of the skin). These medications may be associated, in rare cases, with liver damage.
If any of the following adverse effects occur, discontinue treatment and consult your doctor immediately:
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that is not listed in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medications: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of sight and reach of children.
No special storage conditions are required.
Do not use this medication after the expiration date that appears on the package after CAD. The expiration date is the last day of the month indicated.
Medications should not be disposed of through wastewater or household waste. Deposit the packages and medications that are no longer needed at the SIGRE point of the pharmacy. In case of doubt, ask your pharmacist how to dispose of the packages and medications that are no longer needed. This way, you will help protect the environment.
Composition
Appearance of the product and package contents
Ibufén is presented in the form of a white or almost white oral powder with a marked lemon odor and in monodose sachets of coated paper/polyethylene coextruded/aluminum/polyethylene coextruded.
There are two presentations: packages of 12 units and 24 units.
Only some package sizes may be marketed.
Marketing authorization holder
Laboratorios Cinfa, S.A.
Carretera Olaz-Chipi, 10. Polígono Industrial Areta
31620 Huarte (Navarra) - Spain
Manufacturer
ZINEREO PHARMA, S.L.U.
A Relva, s/n, O Porriño
36410 Pontevedra - Spain
or
FARMALIDER, S.A.
C/Aragoneses, 2
28108 Alcobendas (Madrid) - Spain
or
EDEFARM S.L
Polígono Industrial Enchilagar del Rullo, 117
46191 Villamarchante
(Valencia) - Spain
or
Laboratorios Cinfa, S.A.
Carretera Olaz-Chipi, 10. Polígono Industrial Areta
31620 Huarte (Navarra) - Spain
Date of the last revision of this prospectus: November 2024
"Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/"